Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript August 1, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Renaissance Technologies Jim Simons | 2,468,146 | $339,789,660 | +10% | 0.57% |
2. | AQR Capital Management Cliff Asness | 1,223,055 | $166,959,238 | +23% | 0.25% |
3. | Armistice Capital Steven Boyd | 978,488 | $134,708,443 | -5% | 1.69% |
4. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 940,000 | $129,409,800 | -11% | 3.89% |
5. | Braidwell LP Alex Karnal | 759,009 | $104,492,769 | +4% | 3.27% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
$5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
$5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
$5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
$5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$146.69 | 14,250 | Director | 37,491 | 2024-08-15 | Filing | |
$150.43 | 11,570 | Director | 119,047 | 2024-08-13 | Filing | |
$150.38 | 14,100 | Officer | 31,528 | 2024-08-13 | Filing | |
$150.08 | 4,100 | Officer | 2,507 | 2024-08-13 | Filing | |
$150.13 | 3,043 | Officer | 6,607 | 2024-08-13 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 13,647,891 | $1,798,246,116 | 0.04% | |
2. | 9,710,328 | $1,279,432,817 | 0.02% | |
3. | 4,063,336 | $535,385,151 | 0.02% | |
4. | 2,430,500 | $320,242,680 | 4.89% | |
5. | 2,326,294 | $306,512,662 | 0.02% |